The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2018

Filed:

Feb. 09, 2016
Applicant:

Purdue Pharma L.p., Stamford, CT (US);

Inventors:

Curtis Wright, Rockport, MA (US);

Benjamin Oshlack, Boca Raton, FL (US);

Christopher Breder, Bethesda, MD (US);

Assignees:

Purdue Pharma L.P., Stamford, CT (US);

The P.F. Laboratories, Inc., Totowa, NJ (US);

Purdue Pharmaceuticals L.P., Wilson, NC (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/36 (2006.01); A61K 45/06 (2006.01); A61K 31/485 (2006.01); A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 31/439 (2006.01); A61K 47/38 (2006.01); A61K 47/10 (2017.01); A61K 31/167 (2006.01); A61K 31/192 (2006.01); A61K 9/16 (2006.01); A61K 47/26 (2006.01); A61K 31/48 (2006.01); A61K 9/48 (2006.01); A61K 47/08 (2006.01); A61K 9/50 (2006.01); A61K 47/32 (2006.01); A61K 9/08 (2006.01); A61K 9/28 (2006.01); A61K 47/12 (2006.01); A61K 47/34 (2017.01); A61K 9/06 (2006.01); A61K 31/4458 (2006.01); A61K 31/137 (2006.01); A61K 47/14 (2017.01); A61K 9/70 (2006.01); A61J 3/10 (2006.01); A61K 47/02 (2006.01);
U.S. Cl.
CPC ...
A61K 9/2054 (2013.01); A61J 3/10 (2013.01); A61K 9/0002 (2013.01); A61K 9/006 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/1635 (2013.01); A61K 9/1641 (2013.01); A61K 9/1652 (2013.01); A61K 9/20 (2013.01); A61K 9/205 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2031 (2013.01); A61K 9/2095 (2013.01); A61K 9/28 (2013.01); A61K 9/284 (2013.01); A61K 9/2806 (2013.01); A61K 9/2813 (2013.01); A61K 9/2846 (2013.01); A61K 9/2853 (2013.01); A61K 9/2866 (2013.01); A61K 9/2893 (2013.01); A61K 9/48 (2013.01); A61K 9/485 (2013.01); A61K 9/4808 (2013.01); A61K 9/4833 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4891 (2013.01); A61K 9/5047 (2013.01); A61K 9/5078 (2013.01); A61K 9/5089 (2013.01); A61K 9/70 (2013.01); A61K 31/137 (2013.01); A61K 31/167 (2013.01); A61K 31/192 (2013.01); A61K 31/439 (2013.01); A61K 31/4458 (2013.01); A61K 31/48 (2013.01); A61K 31/485 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/08 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/34 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01);
Abstract

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.


Find Patent Forward Citations

Loading…